Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADC TherapeuticsADCT -2.73%41 3-Year Share Buyback Ratio is -16.00 as of Mar. 2026. GuruFocus rates ADCT with a GF Score™ of 41/100 and a GF Value™ of $2.08 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 647 Drug Manufacturers companies, ADC Therapeutics ranks worse than 81.45% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. ADC Therapeutics's current 3-Year Share Buyback Ratio was -16.00%.
The historical rank and industry rank for ADC Therapeutics's 3-Year Share Buyback Ratio or its related term are showing as below:
ADCT'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -16 Med: -2.4 Max: 0
Current: -16
During the past 10 years, ADC Therapeutics's highest 3-Year Share Buyback Ratio was 0.00%. The lowest was -16.00%. And the median was -2.40%.
ADCT's 3-Year Share Buyback Ratio is ranked worse than 81.45% of 647
companies
in the Drug Manufacturers industry
Industry Median: -2
vs ADCT: -16.00
ADC Therapeutics (NYSE:ADCT) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
ADC Therapeutics 3-Year Share Buyback Ratio Related Terms
ADCT vs LFCR, DERM, BGM: 3-Year Share Buyback Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ADC Therapeutics's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADC Therapeutics 3-Year Share Buyback Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ADC Therapeutics's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where ADC Therapeutics's 3-Year Share Buyback Ratio falls into.
ADC Therapeutics 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -16.00 mean?
ADC Therapeutics (ADCT) has a 3-Year Share Buyback Ratio of -16.00 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for ADC Therapeutics and its competitors. According to the industry distribution chart, ADC Therapeutics ranks #527 out of 647 companies in the Drug Manufacturers industry, placing it in the top 81.5%.
Is ADC Therapeutics' 3-Year Share Buyback Ratio too high?
ADC Therapeutics' current 3-Year Share Buyback Ratio is -16.00. Based on the distribution chart, ADC Therapeutics ranks #527 out of 647 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ADC Therapeutics has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ADC Therapeutics' 3-Year Share Buyback Ratio compare to LFCR and DERM?
According to the Drug Manufacturers industry distribution chart, ADC Therapeutics ranks #527 out of 647 companies for 3-Year Share Buyback Ratio. This places ADC Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for ADC Therapeutics and its competitors. ADC Therapeutics's current 3-Year Share Buyback Ratio is -16.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADC Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, ADC Therapeutics (ADCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.08, compared to a current price of $1.07 — trading 48.6% below its estimated fair value. The current 3-Year Share Buyback Ratio is -16.00. ADC Therapeutics' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For ADC Therapeutics (ADCT), the current 3-Year Share Buyback Ratio is -16.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADC Therapeutics (ADCT) Overvalued in 2026?
Based on GuruFocus' analysis, ADC Therapeutics stock appears to be undervalued.
The current stock price of $1.07 is trading 48.6% below its estimated GF Value™ of $2.08.
GuruFocus considers ADC Therapeutics to be Possible Value Trap.
Key valuation signals for ADCT:
3-Year Share Buyback Ratio: -16.00
GF Value™: $2.08 vs. price of $1.07 (48.6% below fair value)
No single metric tells the full story. See the ADCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
41GF Score
Get the complete analysis for ADCT
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADCT has been successfully added to your 
